Lipid Profile and Total Antioxidant Status in Major Depressive Disorder Patients in North Indian Tertiary Care Hospital: A Case Control Study
Piyush Pathak, Sandeep Kaur, Sandeep Grover, Sant Ram
Keywords :
Antioxidants, Cholesterol, Lipid profile, Major depressive disorder, Triglycerides
Citation Information :
Pathak P, Kaur S, Grover S, Ram S. Lipid Profile and Total Antioxidant Status in Major Depressive Disorder Patients in North Indian Tertiary Care Hospital: A Case Control Study. J Postgrad Med Edu Res 2024; 58 (1):19-23.
Aims and background: Major depressive disorder (MDD) is the most common mental health disorder. It is a multifactorial disease and the pathophysiology is not clear, which results in fewer available options for treatment and more treatment-resistant cases. The development of early diagnostic and prognostic markers will help in the reduction of the burden of this disease. Oxidative stress plays an important role in depression and it is evident that antioxidant effects are exerted by many treatment modalities available for depression. Lipids have a role in inter- and intraneuronal functions of the brain, they can also be developed as markers for MDD.
Materials and methods: In this study, we compared serum antioxidant status and serum lipid profile in MDD patients and healthy controls. A total of 30 MDD patients and 30 healthy controls were included in the study. Serum antioxidant level and serum lipid profile were done using a kit-based method on an autoanalyzer.
Results: The level of antioxidants [mean ± standard deviation (SD)] in controls was 1.332 ± 0.215 mmol/L and in MDD patients was 1.399 ± 0.298 mmol/L, the difference was not significant. The level of total cholesterol in controls was 169.203 ± 31.114 mg/dL and in MDD patients was 193.080 ± 38.876 mg/dL, the difference was statistically significant (p = 0.011). The difference in low-density lipoprotein (LDL), high-density lipoprotein (HDL), and triglycerides (TG) levels was insignificant between healthy controls and MDD patients.
Conclusion: Mixed findings from our study and the various literature suggest that there is a complex association between MDD, antioxidants, and lipid profile, and extensive study is needed in the field.
Clinical significance: The study will be helpful in finding biomarkers for MDD.
World Health Organization, Depression and Other Common Mental Disorders: Global Health Estimates [Internet], Retrieved from World Health Organization, Geneva, Switzerland, 2017. http://apps.who.int/iris/bitstream/10665/254610/1/WHO-MSD-MER-2017.2-eng.pdf?ua=1.
Chiriţă AL, Gheorman V, Bondari D, et al. Current understanding of the neurobiology of major depressive disorder. Rom J Morphol Embryol 2015;56(2 Suppl):651–658. PMID: 26429155.
Mazza MG, Palladini M, Poletti S, et al. Post-COVID-19 depressive symptoms: epidemiology, pathophysiology, and pharmacological treatment. CNS Drugs 2022;36(7):681–702. DOI: 10.1007/s40263-022-00931-3
Paris, Joel. 2014. “The Mistreatment of Major Depressive Disorder Le Traitement Fautif Du Trouble Dépressif Majeur.” CanJ. Paris, Joel. 2014. “The Mistreatment of Major Depressive Disorder Le Traitement Fautif Du Trouble Dépressif Majeur.” CanJPsychiatry 5959(33): 148–51.
Malhi GS, Mann JJ. Depression. Lancet 2018;392(10161):2299–2312. DOI: 10.1016/S0140-6736(18)31948-2
Jiménez-Fernández S, Gurpegui M, Garrote-Rojas D, et al. Oxidative stress parameters and antioxidants in adults with unipolar or bipolar depression versus healthy controls: systematic review and meta-analysis. J Affect Disord 2022;314:211–221. DOI: 10.1016/j.jad.2022.07.015
Lopresti AL, Maker GL, Hood SD, et al. A review of peripheral biomarkers in major depression: the potential of inflammatory and oxidative stress biomarkers. Prog Neuropsychopharmacology Biol Psychiatry 2014;48:102–111. DOI: 10.1016/j.pnpbp.2013.09.017
Moylan S, Berk M, Dean OM, et al. Oxidative & nitrosative stress in depression: why so much stress? Neurosci Biobehav Rev 2014;45:46–62. DOI: 10.1016/j.neubiorev.2014.05.007
Parekh A, Smeeth D, Milner Y, et al. The role of lipid biomarkers in major depression. Healthcare (Basel) 2017;5(1):5. DOI: 10.3390/healthcare5010005
Pinto B, Conde TA, Domingues I, et al. Adaptation of lipid profiling in depression disease and treatment: a critical review. Int J Mol Sci 2022;23(4). DOI: 10.3390/ijms23042032
Bajpai A, Verma AK, Srivastava M, et al. Oxidative stress and major depression. J Clin Diagn Res 2014;8(12):CC04–CC07. DOI: 10.7860/JCDR/2014/10258.5292
Palta P, Samuel LJ, Miller ER 3rd, et al. Depression and oxidative stress: results from a meta-analysis of observational studies. Psychosom Med 2014;76(1):12–19. DOI: 10.1097/PSY.0000000000000009
Huang TL, Lin CC. Advances in Clinical Chemistry Advances in Biomarkers of Major Depressive Disorder, 1st edition. Elsevier Inc; 2015.
Sofic E, Rustembegovic S, Kroyer G, et al. Serum antioxidant capacity in neurological, psychiatric, renal diseases and cardiomyopathy. J Neural Transmission 2002;109(5–6):711–719. DOI: 10.1007/s007020200059
Wu S, Ding Y, Wu F, et al. Serum lipid levels and suicidality: a meta-analysis of 65 epidemiological studies. J Psychiatry Neurosci 2016;41(1):56–69. DOI: 10.1503/jpn.150079
Jordan W, Dobrowolny H, Bahn S, et al. Oxidative stress in drug-naïve first episode patients with schizophrenia and major depression: effects of disease acuity and potential confounders. Eur Arch Psychiatry Clin Neurosci 2018;268(2):129–143. DOI: 10.1007/s00406-016-0749-7
Ceylan D, Yılmaz S, Tuna G, et al. Alterations in levels of 8-Oxo-2’-deoxyguanosine and 8-oxoguanine DNA glycosylase 1 during a current episode and after remission in unipolar and bipolar depression. Psychoneuroendocrinology 2020;114:104600. DOI: 10.1016/j.psyneuen.2020.104600
Bharti V, Bhardwaj A, Hood K, et al. A systematic review and meta-analysis of lipid metabolomic signatures of major depressive disorder. J Psychiatr Res 2021;139:197–205. DOI: 10.1016/j.jpsychires.2021.05.036
Enko D, Brandmayr W, Halwachs-Baumann G, et al. Prospective plasma lipid profiling in individuals with and without depression. Lipids Health Dis 2018;17(1):149. DOI: 10.1186/s12944-018-0796-3
Hocaoglu C, Kural B, Aliyazıcıoglu R, et al. IL-1β, IL-6, IL-8, IL-10, IFN-γ, TNF-α and its relationship with lipid parameters in patients with major depression. Metab Brain Dis 2012;27(4): 425–430. DOI: 10.1007/s11011-012-9323-9
Aliyazicioglu R, Deger O, Kural B, et al. The relationship between the peroxisome proliferator-activated receptor gamma 2 gene polymorphism, lipids and adipokines in patients with major depression. Turk Klin J Med Sci 2011;31(5):1065–1072. DOI: 10.5336/medsci.2010-20010
Papakostas GI, Petersen T, Sonawalla SB, et al. Serum cholesterol in treatment-resistant depression. Neuropsychobiology 2003;47(3):146–151. DOI: 10.1159/000070584
Aksay SS, Bumb JM, Janke C, et al. Serum lipid profile changes after successful treatment with electroconvulsive therapy in major depression: a prospective pilot trial. J Affect Dis 2016;189:85–88. DOI: 10.1016/j.jad.2015.09.037
Stuchtey FC, Block A, Osei F, et al. Lipid biomarkers in depression: does antidepressant therapy have an impact? Healthcare (Basel) 2022;10(2):333. DOI: 10.3390/healthcare10020333
Karlović D, Buljan D, Martinac M, et al. Serum lipid concentrations in Croatian veterans with post-traumatic stress disorder, post-traumatic stress disorder comorbid with major depressive disorder, or major depressive disorder. J Korean Med Sci 2004;19(3):431–436. DOI: 10.3346/jkms.2004.19.3.431
Das PP, Malhotra S, Chakrabarti S, et al. Elevated total cholesterol in severely depressed patients: role in cardiovascular risk? World J Biol Psychiatry 2010;11(2 Pt 2):1–8. DOI: 10.1080/15622970902960889
van der Heijden AR, Houben T. Lipids in major depressive disorder: new kids on the block or old friends revisited? Front Psychiatry 2023;14:1213011. DOI: 10.3389/FPSYT.2023.1213011